Patents by Inventor Sameer KAWATKAR
Sameer KAWATKAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912727Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.Type: GrantFiled: July 10, 2023Date of Patent: February 27, 2024Assignee: AstraZeneca ABInventors: Scott Nathan Mlynarski, Tyler Grebe, Sameer Kawatkar, Maurice Raymond Verschoyle Finlay, Iain Simpson, Jianyan Wang, Steve Cook, Dedong Wu
-
Publication number: 20230365599Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.Type: ApplicationFiled: July 10, 2023Publication date: November 16, 2023Inventors: Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
-
Publication number: 20230122859Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.Type: ApplicationFiled: July 15, 2022Publication date: April 20, 2023Inventors: Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
-
Publication number: 20220267356Abstract: Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cancer or a respiratory inflammatory disease using the same: wherein R1 is selected from hydrogen, —CH3 and —(C?O)CH(R1a)NH2; R1a is C1-C4 alkyl; Y is —(CH2)n— or —(C?O)—; n is an integer selected from 1 and 2; R2 is selected from hydrogen, —CH3 and —(C?X)R4 and R3 is hydrogen or —CH3; or R2 and R3, together with the nitrogen to which they are attached, are linked to form a 6-membered heterocyclic ring; X is NH or O; R4 is —CH3 or —[CH(R4a)]mNH2; m is an integer selected from 0 or 1; and R4a is hydrogen or C1-C6 alkyl.Type: ApplicationFiled: July 22, 2020Publication date: August 25, 2022Inventors: Scott Nathan MLYNARSKI, Jason SHIELDS, Sameer KAWATKAR, Qing YE, Haixia WANG, Xiaolan ZHENG, Ray FINLAY, Iain SIMPSON
-
Patent number: 11420984Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.Type: GrantFiled: February 15, 2019Date of Patent: August 23, 2022Assignee: AstraZeneca ABInventors: Scott Nathan Mlynarski, Tyler Grebe, Sameer Kawatkar, Maurice Raymond Verschoyle Finlay, Iain Simpson, Jianyan Wang, Steve Cook, Dedong Wu
-
Publication number: 20220119372Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 28, 2021Publication date: April 21, 2022Inventors: Annika Birgitta Margareta ASTRAND, Neil Patrick GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
-
Publication number: 20220106335Abstract: Disclosed are compounds of formula (Ib) or (Vc), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer, respiratory inflammatory disease, and inhibiting arginase; wherein R is —H or —C(O)CH(R1a)NHR1b; and R1a is selected from —H, —(C1-C4) alkyl and CH2OR1c; R1b is —H; or alternatively, R1a and R1b, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1c is H or —CH3.Type: ApplicationFiled: February 7, 2020Publication date: April 7, 2022Inventors: Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON
-
Patent number: 11247983Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 28, 2020Date of Patent: February 15, 2022Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.Inventors: Annika Birgitta Margareta Astrand, Neil Patrick Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K. Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
-
Publication number: 20210078981Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 28, 2020Publication date: March 18, 2021Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.Inventors: Annika Birgitta Margareta ASTRAND, Neil Patrick GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
-
Publication number: 20210002305Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.Type: ApplicationFiled: February 15, 2019Publication date: January 7, 2021Inventors: Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
-
Patent number: 10654835Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 20, 2018Date of Patent: May 19, 2020Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.Inventors: Annika Birgitta Margareta Astrand, Neil Patrick Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K. Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
-
Publication number: 20190092760Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 20, 2018Publication date: March 28, 2019Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
-
Patent number: 10167276Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 22, 2017Date of Patent: January 1, 2019Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.Inventors: Annika Astrand, Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
-
Publication number: 20170320857Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 22, 2017Publication date: November 9, 2017Applicant: AstraZeneca ABInventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
-
Patent number: 9714236Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 22, 2016Date of Patent: July 25, 2017Assignee: ASTRAZENECA ABInventors: Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Qibin Su, Melissa Vasbinder, Claudio Edmundo Chuaqui
-
Publication number: 20170088543Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 22, 2016Publication date: March 30, 2017Applicant: AstraZeneca ABInventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, Dedong WU, Wenzhan YANG, Tudor GRECU, James MCCABE
-
Patent number: 8841282Abstract: The present invention relates to pyrrolidinone benzenesulfonamides of the following formula: useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, such as pain.Type: GrantFiled: August 15, 2013Date of Patent: September 23, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Dean Stamos, Esther Ann Martinborough, Nicole Hilgraf, Timothy Donald Neubert, Mehdi Numa, Tara Whitney, Aarti Sameer Kawatkar
-
Publication number: 20130338119Abstract: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: August 15, 2013Publication date: December 19, 2013Applicant: Vertex Pharmaceuticals IncorporatedInventors: Dean Stamos, Esther Ann Martinborough, Nicole Hilgraf, Timothy Donald Neubert, Mehdi Numa, Tara Whitney, Aarti Sameer Kawatkar
-
Patent number: 8586589Abstract: The present invention relates to piperidine and piperazine phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain.Type: GrantFiled: October 2, 2012Date of Patent: November 19, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Esther Martinborough, Lev T. D. Fanning, Urvi Sheth, Dean Wilson, Andreas P. Termin, Timothy D. Neubert, Nicole Hilgraf, Tara Leanne Hampton, Tara Whitney, Aarti Sameer Kawatkar, Danielle Lehsten, Dean Stamos, Jinglan Zhou, Vijayalaksmi Arumugam, Corey Anderson
-
Patent number: 8492403Abstract: Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.Type: GrantFiled: January 21, 2013Date of Patent: July 23, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Aarti Sameer Kawatkar, Esther Ann Martinborough, Nicole Hilgraf, Andreas P. Termin, Timothy Donald Neubert